Bridge Biotherapeutics' BBT-877, a first-in-class autotaxin inhibitor, is undergoing Phase 2 trials with data expected in April, showing promising safety and efficacy.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.